Opus Genetics, Inc. Lease, Cost
Opus Genetics, Inc. (IRD) reported Lease, Cost of $40.29 thousand for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-10-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2020-10-29
- Opus Genetics, Inc. lease, cost for the quarter ending 2020-09-30 was $40.29K, a 1.69% increase year-over-year.
- Opus Genetics, Inc. lease, cost for the quarter ending 2020-06-30 was $42.88K, a 20.28% decline year-over-year.
- Opus Genetics, Inc. lease, cost for the quarter ending 2020-03-31 was $42.46K, a 55.90% decline year-over-year.
- Opus Genetics, Inc. lease, cost for the quarter ending 2019-12-31 was $40.00K.
- Opus Genetics, Inc. lease, cost for fiscal 2019 was $229.70K.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2020-09-30 | $40.29K 10-Q · filed 2020-10-29 | $83.17K derived: sum of 2 quarters · filed 2020-10-29 | $125.64K 10-Q · filed 2020-10-29 | $165.63K derived: sum of 4 quarters · filed 2020-10-29 |
| 2020-06-30 | $42.88K 10-Q · filed 2020-08-14 | $85.34K 10-Q · filed 2020-08-14 | $125.34K derived: sum of 3 quarters · filed 2020-08-14 | $164.97K derived: sum of 4 quarters · filed 2020-10-29 |
| 2020-03-31 | $42.46K 10-Q · filed 2020-05-07 | $82.46K derived: sum of 2 quarters · filed 2020-05-07 | $122.09K derived: sum of 3 quarters · filed 2020-10-29 | $175.87K derived: sum of 4 quarters · filed 2020-10-29 |
| 2019-12-31 | $40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $79.62K derived: sum of 2 quarters · filed 2020-10-29 | $133.41K derived: sum of 3 quarters · filed 2020-10-29 | $229.70K 10-K · filed 2020-02-21 |
| 2019-09-30 | $39.63K 10-Q · filed 2020-10-29 | $93.41K derived: sum of 2 quarters · filed 2020-10-29 | $189.71K 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $53.79K 10-Q · filed 2020-08-14 | $150.08K 10-Q · filed 2020-08-14 | ||
| 2019-03-31 | $96.29K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |